Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
For patients doing well on targeted therapies (alectinib, osimertinib) for metastatic NSCLC, what data / guidelines do you use to decide about holding treatment before/after surgical procedures?
Related Questions
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
What are your treatment options and preferences for classical EGFR mutated NSCLC upon widespread progression following first line chemo/osimertinib ?
How would you treat patient with a stage IV lung adenocarcinoma, an exon 21 p.H835L mutation, high TMB, and negative PD-L1?
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
